Tissue Regenix (LON:TRX) are a medical technology company which uses a proprietary technology platform to make replacement body parts from biological (animal) materials.This proprietary platform, known as the dCELL® technology platform, works by removing all cells (decellularisation) from the animal tissue allowing it to be used to replace worn out or diseased body parts.The dCELL® process can be used to make 20-30 different products. The three priority markets for the application of the technology are: Vascular; Cardiac; and Orthopaedics.The market for human therapeutic products employing tissue engineering is one of the most rapidly growing sectors within the medical products market.Once regulatory approvals have been obtained, Tissue Regenix will look to license dCELL® Technology to third parties and enter co-marketing and/or distribution agreements.
Recent Developments and Milestones* ( May 2013 )
More than half of patients involved in the first trial of a new treatment for chronic leg ulcers have had their wounds completely healed. This trial of a new clinical product, produced by NHS Blood and Transplant (NHSBT) Tissue Services, used a novel graft prepared using Tissue Regenix’ dCELL® technology from skin donated by deceased tissue donors and processed to remove all the donor cells. The therapy involves a graft, known as dCELL® Human Dermis, which is not rejected by the patients’ immune system. It maintains the essential structure of normal skin and serves as an ideal scaffold for the patients’ cells to migrate into and regenerate living, functional skin tissue.
dCELL® dermis works by taking human donor skin and removing the DNA and cells, using Tissue Regenix’ patented process, to leave a dermis matrix that can be placed over the wound to aid natural healing. Lower limb ulcers, which are often secondary to other conditions such as poor circulation and diabetes, are a common age-related condition which is increasing in frequency with an aging and increasingly unfit population.Care and treatment of chronic leg ulcers is estimated to consume 1% of the NHS total budget¹. Our research and development of a treatment that can heal these wounds may lead to better use of NHS resources and greatly improve patients’ quality of life.
This is a significant development for NHSBT and Tissue Regenix. Tissue Regenix has partnered with NHSBT to develop dermis treatments using the dCELL® technology. This dCELL® Dermis clinical treatment has the potential to help many patients and…
